Genesis Technology Group Retains CCG Elite (China)
This article was originally published in PharmAsia News
Genesis Technology Group Inc., one of China's top drug-makers, has retained the services of CCG Elite. Genesis hopes CCG will help it expand investor interest in the company. Genesis works with its subsidiary Lauyang Jiangbo Biotech Technologies Co. to develop and produce a number of drugs. Currently, its pipeline includes both Western drugs and traditional Chinese medicines. This year Genesis has seen total sales of $76.2 million, up a staggering 55 percent from 2006. As one of the largest non-state-owned pharmaceutical companies in China, Genesis is in an excellent position to access the country's fast-growing drug market. Experts expect the market to grow by over 13 percent in the next few years, reaching $51 billion by 2010. (Click here for more
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.